Pharma article - September 23, 2026
WHO review names SynAct’s resomelagon among six dengue candidates
The World Health Organization (WHO) has identified SynAct Pharma's resomelagon as one of six dengue drug candidates with evidence supporting further clinical development, according to a review published in The Lancet Microbe.
Collaboration - September 16, 2026
Swedish healthcare delegation visits Kyiv as Russian attacks on civilians intensify
A Swedish healthcare delegation traveled to Kyiv on September 2–4 to strengthen cooperation on rebuilding Ukraine's healthcare system, timed to one of the most difficult periods for the city in months.
Business article - September 11, 2026
The price of access: Industry and regulators are at odds over Nordic drug costs
The ongoing struggle in the Nordic countries to keep prescription drug prices affordable without shutting out innovative, more expensive therapies continues to frustrate pharmaceutical companies as the introduction of new drugs to the region slows.
Clinical Trials - September 9, 2026
Novo Nordisk’s semaglutide moves obesity below threshold in nearly half of children in phase 3 trial
In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.
Europe - July 6, 2026
New European initiative to accelerate drug discovery for cardiometabolic diseases
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs).
Pharma article - June 10, 2026
Nose to nose with the future of drug delivery
Once limited to decongestants, nasal drug delivery is emerging as one of medicine’s most promising frontiers, offering faster uptake, stronger immunity, and the potential to block transmission before disease takes hold.
